{"id":22297,"date":"2023-02-07T11:23:49","date_gmt":"2023-02-07T19:23:49","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=22297"},"modified":"2026-03-20T15:37:23","modified_gmt":"2026-03-20T22:37:23","slug":"kanjinti-trastuzumab-anns-drug-information","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/","title":{"rendered":"Informaci\u00f3n del medicamento Kanjinti (Trastuzumab-anns)"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Kanjinti fue aprobado por primera vez por la FDA en 2019 como un biosimilar de un medicamento contra el c\u00e1ncer ya comercializado llamado <a href=\"https:\/\/www.herceptin.com\/\">Herceptin<\/a>Se clasifica en la categor\u00eda farmacol\u00f3gica de antineopl\u00e1sicos, anticuerpos monoclonales y f\u00e1rmacos anti-HER2. El principio activo de Kajinti es &quot;trastuzumab-anns&quot;.<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Este medicamento est\u00e1 dise\u00f1ado para retardar el crecimiento de c\u00e1nceres g\u00e1stricos y de mama metast\u00e1sicos con sobreexpresi\u00f3n de HER2 (en etapas tempranas y metast\u00e1sicos) en adultos. Los c\u00e1nceres con HER2 suelen comenzar cuando las prote\u00ednas HER2 crecen y se dividen de forma descontrolada, lo que provoca una sobreexpresi\u00f3n de estas prote\u00ednas.&nbsp;<\/span><\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#What_Is_Kanjinti_Used_To_Treat\" >\u00bfPara qu\u00e9 se utiliza el Kanjinti?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#How_Does_Kanjinti_Work\" >\u00bfC\u00f3mo funciona Kanjinti?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#Mechanism_of_Action\" >Mecanismo de acci\u00f3n<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#In_Which_Cancer_Patients_Is_Kanjinti_Used\" >\u00bfEn qu\u00e9 pacientes con c\u00e1ncer se utiliza Kanjinti?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#Is_Kanjinti_the_Same_as_Herceptin\" >\u00bfEs Kanjinti lo mismo que Herceptin?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#Dosage_Form_and_Strengths\" >Forma farmac\u00e9utica y concentraciones<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#Dosage_and_Schedule\" >Dosis y pauta<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#Dosage_for_Early_Breast_Cancer\" >Dosis para el c\u00e1ncer de mama en etapa temprana<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#Dosage_for_Metastatic_Breast_Cancer\" >Dosis para el c\u00e1ncer de mama metast\u00e1sico<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#Dosage_for_Metastatic_Gastric_Cancer\" >Dosis para el c\u00e1ncer g\u00e1strico metast\u00e1sico<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#How_Is_Kanjinti_Used\" >\u00bfC\u00f3mo se utiliza Kanjinti?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#Is_Kanjinti_a_Chemotherapy_Drug\" >\u00bfEs Kanjinti un f\u00e1rmaco de quimioterapia?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#Side_Effects\" >Efectos secundarios<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#Precautions\" >Precauciones<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#Cost\" >Costo<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_Kanjinti_Used_To_Treat\"><\/span>\u00bfPara qu\u00e9 se utiliza el Kanjinti?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Kanjinti ha sido aprobado para las indicaciones etiquetadas de c\u00e1ncer de adenocarcinoma g\u00e1strico o de la uni\u00f3n gastroesof\u00e1gica metast\u00e1sico, as\u00ed como c\u00e1ncer de mama (tanto en forma temprana como metast\u00e1sica).&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Kanjinti se puede prescribir en las siguientes condiciones:<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">En el c\u00e1ncer de mama temprano (donde el c\u00e1ncer se localiza dentro de la mama y no se propaga m\u00e1s all\u00e1 de la mama o los ganglios linf\u00e1ticos a otras partes del cuerpo), el tratamiento con Kanjinti puede iniciarse despu\u00e9s de la cirug\u00eda. <a href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/bendeka-bendamustine\/\">quimioterapia<\/a>y radioterapia. Puede utilizarse como agente \u00fanico (si el paciente ha recibido quimioterapia previamente) o en combinaci\u00f3n con otros f\u00e1rmacos quimioterap\u00e9uticos como paclitaxel o <a href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/docetaxel-taxotere\/\">docetaxel<\/a>.&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">En el c\u00e1ncer de mama metast\u00e1sico (cuando el tumor se ha diseminado a otras partes del cuerpo), el Kanjinti puede usarse solo si ning\u00fan otro tratamiento ha demostrado ser eficaz. Tambi\u00e9n puede usarse en pacientes que hayan recibido una o m\u00e1s sesiones de quimioterapia. Si las pacientes no han recibido quimioterapia ni ning\u00fan otro tratamiento previamente, el Kanjinti se usa en combinaci\u00f3n con medicamentos quimioterap\u00e9uticos (p. ej., paclitaxel).<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">En el c\u00e1ncer g\u00e1strico (de est\u00f3mago) metast\u00e1sico, Kanjinti se puede utilizar solo o en combinaci\u00f3n con otros medicamentos de quimioterapia (cisplatino y <a href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/capecitabine-xeloda\/\" type=\"link\" id=\"https:\/\/ameripharmaspecialty.com\/discontinued\/capecitabine-xeloda\/\">capecitabina<\/a>), especialmente en pacientes que no han recibido ning\u00fan tratamiento previo.<\/span><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Does_Kanjinti_Work\"><\/span>\u00bfC\u00f3mo funciona Kanjinti?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">HER2 es una prote\u00edna promotora del crecimiento presente en la superficie de las c\u00e9lulas sanas y cancerosas. Sin embargo, en el caso de las c\u00e9lulas cancerosas, las prote\u00ednas HER2 son hiperactivas y env\u00edan se\u00f1ales intensas a las c\u00e9lulas cancerosas a trav\u00e9s de su v\u00eda de se\u00f1alizaci\u00f3n HER. Al recibir se\u00f1ales de HER2, las c\u00e9lulas cancerosas producen mol\u00e9culas que promueven el crecimiento de los vasos sangu\u00edneos, lo que ayuda a nutrir los tumores al proporcionarles nutrientes.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Kanjinti act\u00faa bloqueando el mecanismo de se\u00f1alizaci\u00f3n de HER2 y previniendo el crecimiento tumoral.<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Mechanism_of_Action\"><\/span>Mecanismo de acci\u00f3n<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Kanjinti contiene una sustancia activa,<\/span><span style=\"font-weight: 400;\"> \u201ctrastuzumab-anns\u201d, un anticuerpo monoclonal recombinante <\/span><span style=\"font-weight: 400;\">Dise\u00f1ado para reconocer y unirse a la prote\u00edna HER2, genera una v\u00eda t\u00f3xica celular dependiente de anticuerpos, impidiendo que las c\u00e9lulas HER2 se multipliquen y sobreexpresen.&nbsp; <\/span><span style=\"font-weight: 400;\">Kanjinti tambi\u00e9n atrae a las c\u00e9lulas inmunes para atacar y matar las c\u00e9lulas cancerosas.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"In_Which_Cancer_Patients_Is_Kanjinti_Used\"><\/span>\u00bfEn qu\u00e9 pacientes con c\u00e1ncer se utiliza Kanjinti?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Kanjinti solo se puede utilizar en pacientes cuyo tumor haya sido analizado <\/span><a href=\"https:\/\/www.cancer.org\/cancer\/breast-cancer\/understanding-a-breast-cancer-diagnosis\/breast-cancer-her2-status.html\"><span style=\"font-weight: 400;\">HER2 positivo<\/span><\/a><span style=\"font-weight: 400;\"> debido a las grandes cantidades de prote\u00ednas HER2 que se expresan en las c\u00e9lulas cancerosas y ayudan a que las c\u00e9lulas crezcan sin control y se propaguen r\u00e1pidamente.<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">HER2 sobreexpresado en 25% a 30% en c\u00e1ncer de mama humano. La sobreexpresi\u00f3n de HER2 se observa t\u00edpicamente tanto en c\u00e1nceres tempranos como metast\u00e1sicos.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Kanjinti_the_Same_as_Herceptin\"><\/span>\u00bfEs Kanjinti lo mismo que Herceptin?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Kanjinti es un biosimilar de <\/span><span style=\"font-weight: 400;\">Herceptin, lo que significa que es una versi\u00f3n muy similar del medicamento de marca original (Herceptin). Kanjinti <\/span><span style=\"font-weight: 400;\">comparte los mismos atributos que Herceptin en t\u00e9rminos de <\/span><b>estructura, modo de acci\u00f3n<\/b> <span style=\"font-weight: 400;\">(actividad biol\u00f3gica),<\/span> <b>pureza, <\/b><span style=\"font-weight: 400;\">y <\/span><b>potencia<\/b><span style=\"font-weight: 400;\"> (seguridad y eficacia).&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">No existe ninguna diferencia cl\u00ednicamente significativa entre Kanjinti y Herceptin. Kanjinti tiene el mismo mecanismo de acci\u00f3n, beneficios y efectos secundarios que Herceptin.&nbsp;<\/span><\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"281\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/kanjinti-vial.jpg\" alt=\"A vial of Kanjinti\" class=\"wp-image-22299\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/kanjinti-vial.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/kanjinti-vial-300x201.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/kanjinti-vial-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/kanjinti-vial-86x58.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/kanjinti-vial-167x112.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/kanjinti-vial-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/kanjinti-vial-370x248.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dosage_Form_and_Strengths\"><\/span>Forma farmac\u00e9utica y concentraciones<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">El Kanjinti se presenta en forma de polvo de color blanco a amarillo p\u00e1lido en un vial inyectable y solo se puede obtener con receta m\u00e9dica. Este polvo se disuelve en agua est\u00e9ril antes de su administraci\u00f3n.&nbsp;<\/span><span style=\"font-weight: 400;\">&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Kanjinti est\u00e1 disponible en un vial de dosis \u00fanica de 150 mg (que contiene 150 mg de Kanjinti) y un vial de dosis m\u00faltiple de 420 mg (que contiene 420 mg de Kanjinti).&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dosage_and_Schedule\"><\/span>Dosis y pauta<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">La dosis de Kanjinti es diferente para el c\u00e1ncer g\u00e1strico y el c\u00e1ncer de mama (tanto en estadio temprano como metast\u00e1sico). Las dosis de Kanjinti se ajustan en estos pacientes seg\u00fan los siguientes criterios:<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">Peso corporal del paciente<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Expresi\u00f3n de las prote\u00ednas HER2<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Plan de tratamiento: \u00bfSe administrar\u00e1 Kanjinti solo o en combinaci\u00f3n con un tratamiento adyuvante (como quimioterapia)?&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Frecuencia del tratamiento: \u00bfSe administrar\u00e1 Kanjinti una vez por semana o una vez cada tres semanas?<\/span><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dosage_for_Early_Breast_Cancer\"><\/span>Dosis para el c\u00e1ncer de mama en etapa temprana<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">La dosis inicial recomendada de Kanjinti para pacientes con c\u00e1ncer de mama temprano que tambi\u00e9n reciben quimioterapia es de 4 mg\/kg administrada por v\u00eda intravenosa durante 90 minutos.&nbsp;<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">Dosis inicial: si la primera dosis es bien tolerada, el tiempo de infusi\u00f3n intravenosa se acorta a 30 minutos con una dosis posterior de 2 mg\/kg semanal durante la quimioterapia durante las primeras 12 semanas (para pacientes que toman docetaxel o paclitaxel) o 18 semanas (para pacientes que toman carboplatino y docetaxel).&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Los pacientes generalmente completan un total de 52 semanas de terapia.<\/span><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dosage_for_Metastatic_Breast_Cancer\"><\/span>Dosis para el c\u00e1ncer de mama metast\u00e1sico<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">La dosis inicial de Kanjinti solo o en combinaci\u00f3n con paclitaxel es de 4 mg\/kg durante 90 minutos de infusi\u00f3n intravenosa, seguida de una dosis posterior de 2 mg\/kg cada semana durante 30 minutos hasta la progresi\u00f3n de la enfermedad.<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dosage_for_Metastatic_Gastric_Cancer\"><\/span>Dosis para el c\u00e1ncer g\u00e1strico metast\u00e1sico<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">La dosis inicial de Kanjinti solo es de 8 mg\/kg durante 90 minutos, seguida de una dosis posterior de 6 mg\/kg cada 3 semanas durante 30 a 90 minutos hasta la progresi\u00f3n de la enfermedad.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Is_Kanjinti_Used\"><\/span>\u00bfC\u00f3mo se utiliza Kanjinti?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Kanjinti se administra por v\u00eda intravenosa durante 90 minutos una vez por semana o una vez cada 3 semanas a pacientes con c\u00e1ncer de mama y una vez cada 3 semanas a pacientes con c\u00e1ncer g\u00e1strico metast\u00e1sico.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Los pacientes con c\u00e1ncer de mama en etapa temprana reciben una infusi\u00f3n de Kanjinti durante un a\u00f1o (52 semanas), mientras que los pacientes con c\u00e1ncer de mama metast\u00e1sico y c\u00e1ncer g\u00e1strico reciben infusiones mientras el tratamiento siga siendo efectivo.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Kanjinti_a_Chemotherapy_Drug\"><\/span>\u00bfEs Kanjinti un f\u00e1rmaco de quimioterapia?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">No, Kanjinti es un f\u00e1rmaco inmunoterap\u00e9utico (anticuerpo), pero tambi\u00e9n se utiliza en combinaci\u00f3n con f\u00e1rmacos de quimioterapia, como <\/span><span style=\"font-weight: 400;\">paclitaxel, para obtener mejores resultados.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Side_Effects\"><\/span>Efectos secundarios<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">A continuaci\u00f3n se enumeran algunos de los<\/span> <span style=\"font-weight: 400;\">Efectos secundarios adversos comunes que los pacientes pueden experimentar durante o despu\u00e9s de recibir una infusi\u00f3n de <\/span><span style=\"font-weight: 400;\">Kanjinti.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">En entornos de c\u00e1ncer de mama metast\u00e1sico, los efectos secundarios m\u00e1s comunes experimentados por 10% o m\u00e1s de los pacientes incluyen:&nbsp;<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">Fiebre, escalofr\u00edos y tos.<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Insuficiencia card\u00edaca congestiva<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Infecciones, dolor de cabeza, fatiga.<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">V\u00f3mitos y diarrea<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Erupci\u00f3n&nbsp;<\/span><\/li>\n<\/ul>\n\n\n\n<p><span style=\"font-weight: 400;\">En entornos de c\u00e1ncer g\u00e1strico metast\u00e1sico, los efectos secundarios m\u00e1s comunes experimentados por 10% o m\u00e1s de los pacientes incluyen:&nbsp;<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.cancer.org\/treatment\/treatments-and-side-effects\/physical-side-effects\/low-blood-counts\/neutropenia.html\">Neutropenia<\/a>, anemia<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Fiebre, diarrea, p\u00e9rdida de peso.<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Estomatitis<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Infecciones del tracto respiratorio superior<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Recuento bajo de plaquetas (t<\/span><span style=\"font-weight: 400;\">trombocitopenia)&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Cambios en el gusto (disgeusia)<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Inflamaci\u00f3n de las mucosas<\/span><\/li>\n\n\n\n<li><a href=\"https:\/\/www.bensnaturalhealth.com\/blog\/general-health\/nasopharyngitis\/\"><span style=\"font-weight: 400;\">Nasofaringitis<\/span><\/a><\/li>\n<\/ul>\n\n\n\n<p><span style=\"font-weight: 400;\">En casos graves y adversos pueden ocurrir las siguientes situaciones:&nbsp;<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">Toxicidad pulmonar (da\u00f1o a los pulmones)<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Toxicidad embriofetal (generalmente ocurre en pacientes embarazadas que reciben infusi\u00f3n de Kanjinti)<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/cardiomyopathy#:~:text=What%20is%20cardiomyopathy%3F,to%20arrhythmias%20(irregular%20heartbeats).\">Miocardiopat\u00eda<\/a><\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Exacerbaci\u00f3n de la neutropenia inducida por quimioterapia<\/span><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Precautions\"><\/span>Precauciones<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">No debe iniciar Kanjinti si:&nbsp;<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">Est\u00e1 embarazada o desea quedar embarazada, ya que Kanjinti puede causar toxicidad embriofetal y puede da\u00f1ar al feto.<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Est\u00e1 amamantando o planea amamantar, ya que Kanjinti puede da\u00f1ar a su beb\u00e9 reci\u00e9n nacido.&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Ha tenido previamente una alergia grave al trastuzumab-anns.<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Tiene antecedentes de enfermedades card\u00edacas (como enfermedad coronaria, insuficiencia card\u00edaca y angina de pecho).<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Tiene un problema respiratorio o de presi\u00f3n arterial.<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Usted ha sido tratado previamente con antraciclinas (por ejemplo, doxorrubicina).<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Est\u00e1 tomando otros medicamentos recetados o productos a base de hierbas.&nbsp;<\/span><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cost\"><\/span>Costo<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">El costo de la terapia con Kanjinti puede variar seg\u00fan su plan de seguro, la duraci\u00f3n del tratamiento seg\u00fan el diagn\u00f3stico y la dosis recomendada por tratamiento.<\/span><b>&nbsp;<\/b><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Un<\/span><span style=\"font-weight: 400;\"> El costo estimado del polvo intravenoso Kanjinti (150 mg) para una inyecci\u00f3n es de alrededor de $1,442 y de $4,019.52 para 420 mg.&nbsp;<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>El Kanjinti fue aprobado inicialmente por la FDA en 2019 como biosimilar de un f\u00e1rmaco anticancer\u00edgeno ya comercializado llamado Herceptin. Se clasifica en la categor\u00eda farmacol\u00f3gica de antineopl\u00e1sicos, anticuerpos monoclonales y agentes anti-HER2.<\/p>","protected":false},"author":15,"featured_media":22298,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[64],"tags":[19],"class_list":["post-22297","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-discontinued","tag-dr-rachel-chang"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kanjinti (Trastuzumab-anns) Drug Information<\/title>\n<meta name=\"description\" content=\"Learn about Kanjinti (trastuzumab-anns). This article covers drug information, including how the drug works, precautions, and side effects.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kanjinti (Trastuzumab-anns) Drug Information\" \/>\n<meta property=\"og:description\" content=\"Learn about Kanjinti (trastuzumab-anns). This article covers drug information, including how the drug works, precautions, and side effects.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-07T19:23:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T22:37:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Rachel Chang, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Rachel Chang, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/\"},\"author\":{\"name\":\"Dr. Rachel Chang, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/434b2e8d9065aae5f06dbb47a6fd2b5d\"},\"headline\":\"Kanjinti (Trastuzumab-anns) Drug Information\",\"datePublished\":\"2023-02-07T19:23:49+00:00\",\"dateModified\":\"2026-03-20T22:37:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/\"},\"wordCount\":1223,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/Kanjinti.jpg\",\"keywords\":[\"Dr. Rachel Chang\"],\"articleSection\":[\"Discontinued\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/\",\"name\":\"Kanjinti (Trastuzumab-anns) Drug Information\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/Kanjinti.jpg\",\"datePublished\":\"2023-02-07T19:23:49+00:00\",\"dateModified\":\"2026-03-20T22:37:23+00:00\",\"description\":\"Learn about Kanjinti (trastuzumab-anns). This article covers drug information, including how the drug works, precautions, and side effects.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/Kanjinti.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/Kanjinti.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Kanjinti patient\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/kanjinti-trastuzumab-anns-drug-information\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kanjinti (Trastuzumab-anns) Drug Information\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/434b2e8d9065aae5f06dbb47a6fd2b5d\",\"name\":\"Dr. Rachel Chang, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3ae6774f18bef8df05c572338b8557af3dd277fe9085abf2bc96503ecb5eb65?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3ae6774f18bef8df05c572338b8557af3dd277fe9085abf2bc96503ecb5eb65?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3ae6774f18bef8df05c572338b8557af3dd277fe9085abf2bc96503ecb5eb65?s=96&d=mm&r=g\",\"caption\":\"Dr. Rachel Chang, PharmD\"},\"description\":\"Dr. Rachel Chang, PharmD was born and raised in Hawaii. She received her degree from Marshall B. Ketchum University in 2022, where she graduated with cum laude honors. The most rewarding part of her job is the connections she makes with each patient. She enjoys speaking with each patient and helping them achieve the best treatment possible. In her free time, she likes spending time with her family, traveling, fishing, and mountain biking.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/rachel\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Informaci\u00f3n del medicamento Kanjinti (Trastuzumab-anns)","description":"Inf\u00f3rmese sobre Kanjinti (trastuzumab-anns). Este art\u00edculo cubre informaci\u00f3n sobre el medicamento, incluyendo su acci\u00f3n, precauciones y efectos secundarios.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/","og_locale":"es_MX","og_type":"article","og_title":"Kanjinti (Trastuzumab-anns) Drug Information","og_description":"Learn about Kanjinti (trastuzumab-anns). This article covers drug information, including how the drug works, precautions, and side effects.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2023-02-07T19:23:49+00:00","article_modified_time":"2026-03-20T22:37:23+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg","type":"image\/jpeg"}],"author":"Dr. Rachel Chang, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Rachel Chang, PharmD","Est. reading time":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/"},"author":{"name":"Dr. Rachel Chang, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/434b2e8d9065aae5f06dbb47a6fd2b5d"},"headline":"Kanjinti (Trastuzumab-anns) Drug Information","datePublished":"2023-02-07T19:23:49+00:00","dateModified":"2026-03-20T22:37:23+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/"},"wordCount":1223,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg","keywords":["Dr. Rachel Chang"],"articleSection":["Discontinued"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/","url":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/","name":"Informaci\u00f3n del medicamento Kanjinti (Trastuzumab-anns)","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg","datePublished":"2023-02-07T19:23:49+00:00","dateModified":"2026-03-20T22:37:23+00:00","description":"Inf\u00f3rmese sobre Kanjinti (trastuzumab-anns). Este art\u00edculo cubre informaci\u00f3n sobre el medicamento, incluyendo su acci\u00f3n, precauciones y efectos secundarios.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg","width":1280,"height":853,"caption":"Kanjinti patient"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/kanjinti-trastuzumab-anns-drug-information\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/es\/"},{"@type":"ListItem","position":2,"name":"Kanjinti (Trastuzumab-anns) Drug Information"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/434b2e8d9065aae5f06dbb47a6fd2b5d","name":"Dra. Rachel Chang, Farmac\u00e9utica","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/c3ae6774f18bef8df05c572338b8557af3dd277fe9085abf2bc96503ecb5eb65?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c3ae6774f18bef8df05c572338b8557af3dd277fe9085abf2bc96503ecb5eb65?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3ae6774f18bef8df05c572338b8557af3dd277fe9085abf2bc96503ecb5eb65?s=96&d=mm&r=g","caption":"Dr. Rachel Chang, PharmD"},"description":"La Dra. Rachel Chang, doctora en farmacia, naci\u00f3 y creci\u00f3 en Haw\u00e1i. Se gradu\u00f3 con honores cum laude en la Universidad Marshall B. Ketchum en 2022. Lo m\u00e1s gratificante de su trabajo es la conexi\u00f3n que establece con cada paciente. Disfruta hablando con cada paciente y ayud\u00e1ndolos a obtener el mejor tratamiento posible. En su tiempo libre, le gusta pasar tiempo con su familia, viajar, pescar y practicar ciclismo de monta\u00f1a.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/rachel\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",600,400,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Rachel Chang, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/rachel\/"},"uagb_comment_info":1,"uagb_excerpt":"Kanjinti was first approved by the FDA in 2019 as a biosimilar of an already-marketed anticancer drug called Herceptin. It is classified under the pharmacologic category of antineoplastic, monoclonal antibodies, and anti-HER2 drug agents.","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",600,400,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/02\/Kanjinti.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Rachel Chang, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/rachel\/"},"rttpg_comment":1,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/discontinued\/\" rel=\"category tag\">Discontinued<\/a>","rttpg_excerpt":"Kanjinti was first approved by the FDA in 2019 as a biosimilar of an already-marketed anticancer drug called Herceptin. It is classified under the pharmacologic category of antineoplastic, monoclonal antibodies, and anti-HER2 drug agents.","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/22297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=22297"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/22297\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/22298"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=22297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=22297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=22297"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}